|Bid||10.03 x 800|
|Ask||10.01 x 800|
|Day's Range||9.90 - 10.59|
|52 Week Range||2.12 - 33.79|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Several coronavirus vaccine stocks have slumped as of 11:20 a.m. EDT on Wednesday, dragged down by the broader market sell-off. Shares of Moderna (NASDAQ: MRNA) were 5% lower. Novavax (NASDAQ: NVAX) and Inovio Pharmaceuticals (NASDAQ: INO) were down 6.1% and 4.5%, respectively.
Inovio Pharmaceuticals (NASDAQ: INO) and Gilead Sciences (NASDAQ: GILD) are major competitors in the growing market for coronavirus products, making both tantalizing stock picks. Inovio's stock has soared this year thanks to its INO-4800 coronavirus vaccine project, which has so far proven effective at producing immunity in primates. In contrast, Gilead's stock has consistently struggled despite the commercialization of its antiviral drug, remdesivir, which may be effective at helping patients recover from COVID-19.
Two biotech stocks that certainly fall into that group are Inovio Pharmaceuticals (NASDAQ: INO) and VBI Vaccines (NASDAQ: VBIV). Inovio's shares are up 259% year to date after rising as much as 860% at one point. VBI Vaccines stock is up 109% after jumping as high as 347% in July.